approved for medical use in the United States as the first interchangeable biosimilar of Lantus. The FDA granted approval of Semglee to Mylan Pharmaceuticals Inc. Patent expiry Patent protection for insulin glargine expired in most countries in 2015 and in the U.S.A. is expected to expire on 2027-07-05. Insulin glargine from competitor Eli Lilly became available in most countries during 2015, under the brand names Basaglar (as a follow-on in the US) and Abasaglar (as a biosimilar in the EU). References External links Insulin receptor agonists Insulin therapies Human proteins Recombinant proteins Peptide hormones Wikipedia medicine articles ready to translate Eli Lilly and Company brands Boehringer Ingelheim Sanofi World Health Organization essential medicines